Objective: To explore the protective effect and mechanism of ginsenoside Rb1 (GsRb1) on lipopolysaccharide (LPS)-induced acute lung injury (ALI). Methods: C57BL/6 mice were randomly divided into control group, model group, GsRb1 administration group (low, medium and high dose groups). LPS was given intratracheally to establish the model. The administration group was given intraperitoneal injection of different doses of GsRb1 pretreatment 3 days before modeling. After 12 hours of modeling, the alveolar lavage fluid was collected and the lung tissue was taken out. The lung wet/dry ratio was calculated. The levels of interleukin-6 (IL-6), interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in lavage fluid and the activity of myeloperoxidase (MPO) in lung were detected by kit. The expression of nuclear factor-κB (NF-κB) protein in lung tissue was detected by Western blot. Results: High dose GsRb1 could significantly reduce the wet/dry ratio of lung tissue (P＜0.05). Medium and high doses of GsRb1 could significantly reduce the MPO activity in lung tissue (P＜0.05). High dose GsRb1 could significantly reduces the levels of IL-1β and TNF-α in alveolar lavage fluid of mice (P＜0.05). High dose GsRb1 could significantly reduce the expression of NF-κB p65 protein in lung tissue (P＜0.05). Conclusion: GsRb1 may reduce inflammation response and inhibit LPS-induced ALI in mice by regulating the NF-κB pathway.
SUN Jianfang
,
ZHANG Xuejun
,
SU Shanna
,
HUO Dongsheng
. Effect of ginsenoside Rb1 on alleviating lipopolysaccharide induced acute lung injury[J]. Journal of Baotou Medical College, 2024
, 40(6)
: 20
-24
.
DOI: 10.16833/j.cnki.jbmc.2024.06.004
[1] Camporota L, Cronin JN, Busana M, et al.Pathophysiology of coronavirus-19 disease acute lung injury[J].CurrOpinCrit Care, 2022,28(1):9-16.
[2] Sahetyas K, Golighere C, Browerr G.Fifty years of research in ARDS.setting positive end-expiratory pressure in acute respiratory distress syndrome[J].Am J Respir Crit Care Med, 2017,195(11):1429-1438.
[3] Máca J, Jor O, Holub M, et al.Past and present ARDS mortality rates: asystematic review[J].Respir Care, 2017,62(1):113-122.
[4] Swensonk E, Swensone R.Pathophysiology of acute respiratory distress syndrome and COVID-19 lung injury[J].Crit Care Clin, 2021,37(4):749-776.
[5] Ji QJ, Sun ZR, Yang ZZ, et al.Protective effect of ginsenoside Rg1 on LPS-induced apoptosis of lung epithelial cells[J].MolImmunol, 2021,136:168-174.
[6] Xuh L, Cheng H, Wuy T, et al.Ginsenoside Ro, an oleanolic saponin of Panax ginseng, exerts anti-inflammatory effect by direct inhibiting toll like receptor 4 signaling pathway[J].J Ginseng Res, 2022,46(1):156-166.
[7] Lin Z, Xie RF, Zhong CH, et al.Recent progress (2015-2020) in the investigation of the pharmacological effects and mechanisms of ginsenoside Rb1, a main active ingredient in Panax ginseng Meyer[J].J Ginseng Res, 2022,46(1):39-53.
[8] 郝广煜,方刚,代玉晶,等.人参皂苷Rb1对H2O2诱导PC12细胞损伤的保护作用[J].包头医学院学报,2021,37(12):63-67.
[9] Lid W, Zhouf Z, Sunx C, et al.Ginsenoside Rb1 protects dopaminergic neurons from inflammatory injury induced by intranigral lipopolysaccharide injection[J].Neural Regen Res, 2019,14(10):1814-1822.
[10] 郭玲,李文静,徐明江,等.吸入脂多糖诱导小鼠急性肺炎模型的建立[J].北京大学学报(医学版),2009,41(2):226-229.
[11] Singh N, Baby D, Rajguruj, et al.Inflammation and cancer[J].Ann Afr Med, 2019,18(3):121.
[12] Tang Y, Chen YL, Chu Z, et al.Protective effect of cryptotanshinone on lipopolysaccharide-induced acute lung injury in mice[J].Eur J Pharmacol, 2014,723:494-500.
[13] D’alessiof R.Mouse models of acute lung injury and ARDS[J].Methods MolBiol, 2018,1809:341-350.
[14] Feng G, Sun B, Lit Z.Daidzein attenuates lipopolysaccharide-induced acute lung injury via toll-like receptor 4/NF-kappaB pathway[J].IntImmunopharmacol, 2015,26(2):392-400.
[15] Klebanoffs J.Myeloperoxidase: friend and foe[J].J LeukocBiol, 2005,77(5):598-625.
[16] Ju MJ, Liu BF, He HY, et al.MicroRNA-27a alleviates LPS-induced acute lung injury in mice via inhibiting inflammation and apoptosis through modulating TLR4/MyD88/NF-κB pathway[J].Cell Cycle, 2018,17(16):2001-2018.
[17] Chen CS, Shi L, Li YP, et al.Disease-specific dynamic biomarkers selected by integrating inflammatory mediators with clinical informatics in ARDS patients with severe pneumonia[J].Cell BiolToxicol, 2016,32(3):169-184.
[18] Hirano T.IL-6 in inflammation, autoimmunity and cancer[J].IntImmunol, 2021,33(3):127-148.
